Article: Serono Completes Second Phase III Trial of its Proprietary Recombinant Human Growth Hormone for HIV-Associated Adipose Redistribution Syndrome (HARS).

Successful Completion of Trial Meets Pre-Specified Primary and Major Secondary Endpoints

GENEVA, Switzerland and ROCKLAND, Massachusetts, January 9 /PRNewswire-FirstCall/ -- Serono (virt-x: SEO NYSE: SRA) announced today the completion of its pivotal Phase III double-blind, placebo-controlled trial of Serono's recombinant human growth hormone in the treatment of HIV-associated Adipose Redistribution Syndrome (HARS), which met all pre-specified primary and major secondary endpoints. Serono plans to submit the file to the FDA in the first half of 2006 and expects that the data will be presented at upcoming scientific meetings.

More than 300 patients ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!